Members |
acceptabilityId |
2019-nCoV antigen vaccination |
Acceptable (foundation metadata concept) |
2019-nCoV antigen vaccination not indicated |
Acceptable (foundation metadata concept) |
2019-nCoV antigen vaccine contraindicated |
Acceptable (foundation metadata concept) |
2019-nCoV antigen vaccine declined |
Acceptable (foundation metadata concept) |
2019-nCoV detected |
Acceptable (foundation metadata concept) |
2019-nCoV immunisation |
Acceptable (foundation metadata concept) |
2019-nCoV mRNA immunisation |
Acceptable (foundation metadata concept) |
2019-nCoV mRNA vaccination |
Acceptable (foundation metadata concept) |
2019-nCoV mRNA vaccination not indicated |
Acceptable (foundation metadata concept) |
2019-nCoV mRNA vaccine contraindicated |
Acceptable (foundation metadata concept) |
2019-nCoV mRNA vaccine declined |
Acceptable (foundation metadata concept) |
2019-nCoV non-replicating viral vector immunisation |
Acceptable (foundation metadata concept) |
2019-nCoV non-replicating viral vector vaccination |
Acceptable (foundation metadata concept) |
2019-nCoV non-replicating viral vector vaccine contraindicated |
Acceptable (foundation metadata concept) |
2019-nCoV non-replicating viral vector vaccine declined |
Acceptable (foundation metadata concept) |
2019-nCoV not detected |
Acceptable (foundation metadata concept) |
2019-nCoV recombinant spike protein antigen immunisation |
Acceptable (foundation metadata concept) |
2019-nCoV recombinant spike protein antigen vaccination |
Acceptable (foundation metadata concept) |
2019-nCoV recombinant spike protein antigen vaccine contraindicated |
Acceptable (foundation metadata concept) |
2019-nCoV recombinant spike protein antigen vaccine declined |
Acceptable (foundation metadata concept) |
2019-nCoV vaccination |
Acceptable (foundation metadata concept) |
2019-nCoV vaccination not indicated |
Acceptable (foundation metadata concept) |
2019-nCoV vaccination not indicated |
Acceptable (foundation metadata concept) |
2019-nCoV vaccine contraindicated |
Acceptable (foundation metadata concept) |
2019-nCoV vaccine contraindicated |
Acceptable (foundation metadata concept) |
2019-nCoV vaccine declined |
Acceptable (foundation metadata concept) |
2019-nCoV vaccine declined |
Acceptable (foundation metadata concept) |
2019-nCoV virus-like particle antigen immunisation |
Acceptable (foundation metadata concept) |
2019-nCoV virus-like particle antigen vaccination |
Acceptable (foundation metadata concept) |
2019-nCoV virus-like particle antigen vaccine contraindicated |
Acceptable (foundation metadata concept) |
2019-nCoV virus-like particle antigen vaccine declined |
Acceptable (foundation metadata concept) |
201m-Bi |
Acceptable (foundation metadata concept) |
201m-Pb |
Acceptable (foundation metadata concept) |
202-Bi |
Acceptable (foundation metadata concept) |
202-Pb |
Acceptable (foundation metadata concept) |
202-Tl |
Acceptable (foundation metadata concept) |
202m-Pb |
Acceptable (foundation metadata concept) |
203-Bi |
Acceptable (foundation metadata concept) |
203-Hg |
Acceptable (foundation metadata concept) |
203-Pb |
Acceptable (foundation metadata concept) |
203.6 |
Preferred (foundation metadata concept) |
203.6 (qualifier value) |
Preferred (foundation metadata concept) |
204-Bi |
Acceptable (foundation metadata concept) |
204-Tl |
Acceptable (foundation metadata concept) |
204m-Pb |
Acceptable (foundation metadata concept) |
205-Bi |
Acceptable (foundation metadata concept) |
205-Pb |
Acceptable (foundation metadata concept) |
206-Bi |
Acceptable (foundation metadata concept) |
206-Tl |
Acceptable (foundation metadata concept) |
207-Bi |
Acceptable (foundation metadata concept) |
207-Tl |
Acceptable (foundation metadata concept) |
207m-Pb |
Acceptable (foundation metadata concept) |
208-Bi |
Acceptable (foundation metadata concept) |
208-Tl |
Acceptable (foundation metadata concept) |
208.333 |
Preferred (foundation metadata concept) |
208.333 (qualifier value) |
Preferred (foundation metadata concept) |
209-Bi |
Acceptable (foundation metadata concept) |
209-Pb |
Acceptable (foundation metadata concept) |
209-Tl |
Acceptable (foundation metadata concept) |
20G |
Preferred (foundation metadata concept) |
20G (qualifier value) |
Preferred (foundation metadata concept) |
20M post incubation |
Acceptable (foundation metadata concept) |
20alpha-hydroxysteroid dehydrogenase |
Acceptable (foundation metadata concept) |
20p partial trisomy syndrome |
Preferred (foundation metadata concept) |
20p partial trisomy syndrome (disorder) |
Preferred (foundation metadata concept) |
20p subtelomeric deletion syndrome |
Acceptable (foundation metadata concept) |
20p12.2 deletion syndrome |
Preferred (foundation metadata concept) |
20p12.2 deletion syndrome (disorder) |
Preferred (foundation metadata concept) |
20p12.3 microdeletion syndrome |
Preferred (foundation metadata concept) |
20p12.3 microdeletion syndrome (disorder) |
Preferred (foundation metadata concept) |
20p12.3 microdeletion syndrome is a recently described syndrome characterised by Wolff-Parkinson-White syndrome, variable developmental delay and facial dysmorphism. |
Preferred (foundation metadata concept) |
20p13 microdeletion syndrome |
Preferred (foundation metadata concept) |
20p13 microdeletion syndrome (disorder) |
Preferred (foundation metadata concept) |
20p13 microdeletion syndrome is a rare chromosomal anomaly characterised by developmental delay, mild to moderate intellectual disability, epilepsy, and unspecific dysmorphic signs. High palate, delayed permanent tooth eruption, hypoplastic fingernails, clinodactyly and short fingers have also been reported. |
Preferred (foundation metadata concept) |
20q partial trisomy |
Preferred (foundation metadata concept) |
20q partial trisomy (disorder) |
Preferred (foundation metadata concept) |
20q11.2 microdeletion syndrome |
Preferred (foundation metadata concept) |
20q11.2 microdeletion syndrome (disorder) |
Preferred (foundation metadata concept) |
20q11.2 microduplication syndrome |
Preferred (foundation metadata concept) |
20q11.2 microduplication syndrome (disorder) |
Preferred (foundation metadata concept) |
20q11.2 microduplication syndrome is a rare chromosomal anomaly syndrome, due to partial duplication of the long arm of chromosome 20, characterised by psychomotor and developmental delay, moderate intellectual disability, metopic ridging/trigonocephaly, short hands and/or feet and distinctive facial features (epicanthus, hypoplastic supraorbital ridges, horizontal/downslanting palpebral fissures, small nose with depressed nasal bridge and anteverted nostrils, prominent cheeks, retrognathia and small, thick ears). Growth delay and cryptorchidism are often associated features. |
Preferred (foundation metadata concept) |
20q13.33 microdeletion syndrome |
Preferred (foundation metadata concept) |
20q13.33 microdeletion syndrome (disorder) |
Preferred (foundation metadata concept) |
21 |
Preferred (foundation metadata concept) |
21 (AJCC) |
Acceptable (foundation metadata concept) |
21 (UICC) |
Acceptable (foundation metadata concept) |
21 (qualifier value) |
Preferred (foundation metadata concept) |
21 DAY FLEA & TICK DIP |
Preferred (foundation metadata concept) |
21 DAY FLEA & TICK DIP (product) |
Preferred (foundation metadata concept) |
21 gene breast recurrence score |
Preferred (foundation metadata concept) |
21 gene breast recurrence score (observable entity) |
Preferred (foundation metadata concept) |
21-Hydroxylase antibody assay |
Acceptable (foundation metadata concept) |
21-Ne |
Acceptable (foundation metadata concept) |
21-deoxycorticosterone |
Preferred (foundation metadata concept) |
21-deoxycorticosterone (substance) |
Preferred (foundation metadata concept) |
21-deoxycortisol |
Preferred (foundation metadata concept) |
21-deoxycortisol (substance) |
Preferred (foundation metadata concept) |
21-hydroxylase |
Acceptable (foundation metadata concept) |
21-hydroxylase antibody |
Acceptable (foundation metadata concept) |
21-hydroxylase deficiency |
Acceptable (foundation metadata concept) |
21-hydroxylase deficiency |
Preferred (foundation metadata concept) |